Ladirubicin
Alternative Names: FCE 28729; PNU 159548Latest Information Update: 04 Jul 2006
Price :
$50 *
At a glance
- Originator Pfizer
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics
- Mechanism of Action Alkylating agents; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 04 Jul 2006 No development reported - Phase-II for Breast cancer in Europe (unspecified route)
- 04 Jul 2006 No development reported - Phase-II for Colorectal cancer in Europe (unspecified route)
- 04 Jul 2006 No development reported - Phase-II for Malignant melanoma in Europe (unspecified route)